HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
-2.84%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$1.45B
AUM Growth
+$1.45B
(-20%)
Cap. Flow
-$343M
Cap. Flow
% of AUM
-23.71%
Top 10 Holdings %
Top 10 Hldgs %
42.51%
Holding
79
New
11
Increased
20
Reduced
21
Closed
14
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$47M |
| 2 |
Cytokinetics
CYTK
|
$38.3M |
| 3 |
Becton Dickinson
BDX
|
$37.6M |
| 4 |
Teleflex
TFX
|
$35.2M |
| 5 |
Abbott
ABT
|
$33.4M |
Top Sells
| 1 |
Medtronic
MDT
|
$158M |
| 2 |
Bristol-Myers Squibb
BMY
|
$93.1M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$52.9M |
| 4 |
Johnson & Johnson
JNJ
|
$47.9M |
| 5 |
Tenet Healthcare
THC
|
$42.8M |
Sector Composition
| 1 | Healthcare | 95.52% |
| 2 | Consumer Discretionary | 1.65% |
| 3 | Financials | 0.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Amgen
AMGN
$153B
| $26.3M | 1.76% |
108,890
+46,400
| +74% | +$11.2M |
|
|
27
Tenet Healthcare
THC
$16.5B
| $24.4M | 1.63% |
283,730
-498,450
| -64% | -$42.8M |
|
|
CCXI
28
DELISTED
ChemoCentryx, Inc.
CCXI
| $24M | 1.6% |
956,740
+716,210
| +298% | +$18M |
|
29
Petco
WOOF
$928M
| $23.8M | 1.59% |
1,215,000
-1,514,450
| -55% | -$29.6M |
|
30
Henry Schein
HSIC
$8.14B
| $22.3M | 1.48% |
255,230
+127,620
| +100% | +$11.1M |
|
31
Syndax Pharmaceuticals
SNDX
$1.39B
| $20.5M | 1.37% |
1,180,500
+22,940
| +2% | +$399K |
|
32
Cardinal Health
CAH
$36B
| $18M | 1.2% |
+317,280
| New | +$18M |
|
|
RACB
33
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $12.9M | 0.86% |
1,324,800
| – | – |
|
34
Pfizer
PFE
$141B
| $12.6M | 0.84% |
242,880
-96,230
| -28% | -$4.98M |
|
35
HCA Healthcare
HCA
$95.4B
| $12.3M | 0.82% |
48,890
-35,380
| -42% | -$8.87M |
|
36
Stryker
SYK
$149B
| $11.7M | 0.78% |
43,760
-115,180
| -72% | -$30.8M |
|
|
AFMD
37
DELISTED
Affimed
AFMD
| $7.53M | 0.5% |
172,193
| – | – |
|
38
Quanterix
QTRX
$202M
| $7.2M | 0.48% |
246,540
+112,200
| +84% | +$3.28M |
|
39
Maravai LifeSciences
MRVI
$341M
| $7.05M | 0.47% |
+200,000
| New | +$7.05M |
|
40
Regeneron Pharmaceuticals
REGN
$59.8B
| $6.68M | 0.45% |
9,570
-18,750
| -66% | -$13.1M |
|
|
IMGN
41
DELISTED
Immunogen Inc
IMGN
| $6.24M | 0.42% |
1,310,340
| – | – |
|
42
Hyperfine
HYPR
$88M
| $6.2M | 0.41% |
1,750,000
+1,058,350
| +153% | +$3.75M |
|
43
RAPT Therapeutics
RAPT
$187M
| $5.81M | 0.39% |
33,019
+10,344
| +46% | +$1.82M |
|
|
CANO
44
DELISTED
Cano Health, Inc.
CANO
| $4.52M | 0.3% |
7,120
-8,747
| -55% | -$5.55M |
|
45
BioCryst Pharmaceuticals
BCRX
$1.74B
| $3.72M | 0.25% |
228,450
-2,148,680
| -90% | -$34.9M |
|
46
Alkermes
ALKS
$4.95B
| $3.7M | 0.25% |
+140,630
| New | +$3.7M |
|
47
iShares Biotechnology ETF
IBB
$5.68B
| $3.68M | 0.25% |
+28,220
| New | +$3.68M |
|
48
Stereotaxis
STXS
$246M
| $3.07M | 0.2% |
821,850
+165,310
| +25% | +$617K |
|
49
Merus
MRUS
$5.04B
| $2.96M | 0.2% |
111,760
| – | – |
|
50
Neurocrine Biosciences
NBIX
$13.5B
| $2.2M | 0.15% |
23,480
-342,257
| -94% | -$32.1M |
|